GSK acquires BELLUS Health for $2 billion to boost cough drug pipeline.
TL;DR Summary
GSK has agreed to acquire BELLUS Health, a late-stage biopharmaceutical company, for $2 billion, gaining access to camlipixant, a potential best-in-class treatment for refractory chronic cough. Camlipixant is a highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. The acquisition is expected to be accretive to adjusted EPS from 2027 and has the potential to deliver significant sales through 2031 and beyond.
- GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health GSK
- GSK inks $2B Bellus buyout to challenge Merck for cough market FierceBiotech
- GSK bets $2 bln on Bellus cough drug to soothe pipeline fears Reuters
- Why BELLUS Health Stock Is Rocketing Higher Today The Motley Fool
- BLU Stock Nearly Doubles On $2 Billion GSK Takeover; GSK Stock Flounders Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
9 min
vs 10 min read
Condensed
96%
1,832 → 71 words
Want the full story? Read the original article
Read on GSK